Collectively, these data suggest that GFH009 depletes the protective anti-apoptotic proteins produced downstream of CDK9 in both in vitro and in vivo (murine) models of hematologic malignancies, meriting further investigation as a potential treatment for hematological cancers, more specifically AML, in clinical settings. The gene discussed is CDK9; the disease is hematopoietic and lymphoid cell neoplasm.